Section Arrow
Quote
CVKD.NASDAQ
- Cadrenal Therapeutics Inc
Quotes are at least 15-min delayed:2026/06/06 04:57 EDT
Regular Hours
Last
 4.44
+0.13 (+3.02%)
Day High 
4.52 
Prev. Close
4.31 
1-M High
6.74 
Volume 
58.94K 
Bid
4.1
Ask
5.5
Day Low
4.27 
Open
4.27 
1-M Low
4.145 
Market Cap 
13.27M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.8 
20-SMA 5.07 
50-SMA 5.21 
52-W High 15.99 
52-W Low 4.145 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.59/-3.42
Enterprise Value
13.27M
Balance Sheet
Book Value Per Share
0.58
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BCDABioCardia Inc.1.03+0.111+12.08%-- 
BGMSBio Green Med Solution Inc1.5+0.44+41.51%0.3PE
CMNDClearmind Medicine Inc.3.98+1.07+36.77%-- 
ADTXAditxt Inc.0.0621-0.0149-19.35%-- 
RXRXRecursion Pharmaceuticals3.315-0.485-12.76%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.